Citius Oncology, Inc. CTOR Payments Of Merger Related Costs Financing Activities

Payments Of Merger Related Costs Financing Activities at other companies

CTO

Citius Oncology, Inc.CTOR

$688.57K—

Victory Capital Holdings, Inc.VCTR

$39.94M—

TuHURA Biosciences, Inc.HURA

$500K-44.9%

Newmark Group, Inc.NMRK

$0-100%

Installed Building ProductsIBP

$700K+75.0%

Fluence Energy, Inc.FLNC

$1.47M+4.7%

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Operating cash flow-$3.8M-179%

Market cap$60.45M-74.7%

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities.

The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Citius Oncology, Inc.'s payments of merger related costs financing activities?: Citius Oncology, Inc. (CTOR) reported payments of merger related costs financing activities of $688.57K in Q3 2024.
What does payments of merger related costs financing activities mean?: Captures cash outflows specifically associated with the financing aspects of merger and acquisition transactions, such as fees paid to underwriters or lenders. Monitoring these costs helps investors understand the total capital burden of inorganic growth strategies.